1. Home
  2. PESI vs SKYE Comparison

PESI vs SKYE Comparison

Compare PESI & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Perma-Fix Environmental Services Inc.

PESI

Perma-Fix Environmental Services Inc.

HOLD

Current Price

$11.79

Market Cap

243.9M

Sector

Industrials

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$0.64

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PESI
SKYE
Founded
1990
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Environmental Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
243.9M
44.9M
IPO Year
1996
2013

Fundamental Metrics

Financial Performance
Metric
PESI
SKYE
Price
$11.79
$0.64
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$14.75
AVG Volume (30 Days)
126.0K
285.7K
Earning Date
05-07-2026
03-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$60,030,000.00
N/A
Revenue This Year
$9.91
N/A
Revenue Next Year
$62.48
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.25
$0.64
52 Week High
$16.50
$5.75

Technical Indicators

Market Signals
Indicator
PESI
SKYE
Relative Strength Index (RSI) 31.78 39.87
Support Level $11.01 N/A
Resistance Level $12.37 $0.83
Average True Range (ATR) 0.71 0.05
MACD -0.15 -0.00
Stochastic Oscillator 2.85 11.08

Price Performance

Historical Comparison
PESI
SKYE

About PESI Perma-Fix Environmental Services Inc.

Perma-Fix Environmental Services Inc is a provider of both nuclear services and the management of nuclear and mixed waste. The company operates through two segments: The treatment segment offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: